Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy

Reuters

2025/07/15

Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy

Apellis Pharmaceuticals Inc. has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration $(AMD)$. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2551690991"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551690991\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551690991?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-15 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551690991","market":"fut","top_or_hot":-1,"title":"Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals Inc.</a> has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-15 19:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/APLS\">Apellis Pharmaceuticals Inc.</a> has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration <a href=\"https://laohu8.com/S/AMD\">$(AMD)$</a>. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250715:nNDL9lv1Ys:1","article_id":"2551690991","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551690991","pubTimestamp":1752577257,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Apellis Pharmaceuticals Unveils New Data on SYFOVRE Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on July 15, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4505":"高瓴资本持仓","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","APLS":"Apellis Pharmaceuticals Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股"},"translate_title":"Apellis Pharmaceuticals公布SYFOVRE新数据®ASRS会议上的疗效，强调地理萎缩的治疗进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"APLS":0.9},"content_text":"Apellis Pharmaceuticals Unveils New Data on SYFOVRE® Efficacy at ASRS Meeting, Highlighting Treatment Advances for Geographic Atrophy\n    \n\nApellis Pharmaceuticals Inc. has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration $(AMD)$. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apellis Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9494313-en) on July 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}